



NIH AIDS Reagent Program

20301 Century Boulevard
Building 6, Suite 200
Germantown, MD 20874
USA

Phone: 240 686 4740
Fax: 301 515 4015
aidsreagent.org

DATA SHEET

Reagent: ☒ SHIV-1157ipEL-p, harvest day 9

Catalog Number: 12192

Lot Number: 1_12/02/09-0.5mL OR 1-12/02/09-1.0mL

Release Category: C

Provided: 0.5 mL
1.0 mL
Please indicate desired volume when ordering.
TCID50 = 3.2×10^5 TCID50/mL
p27 = 407 ng/mL

Original Source: This virus is a chimera of the "early" neutralization sensitive SHIV-1157ip envelope and the "late" engineered backbone of SHIV-1157ipd3N4, which was engineered to have extra NF-KB sites in the LTRs. The envelope gene was derived from a relatively recently transmitted pediatric R5 Subtype C isolate from Zambia.

Host Strain: RM PBMC

Description: SHIV-1157ipEL-p is a tier 1 R5 Subtype C SHIV.

Special Characteristics: SHIV-1157ipEL-p is a biological isolate that is exclusively R5 tropic and mucosally transmissible. It causes T-cell depletion during acute infection and gradual progression to AIDS. SHIV-1157ipEL-p has been used as a challenge virus in passive and active immunization studies.

Recommended Storage: Keep the reagent in liquid nitrogen.

Contributor: Dr. Ruth Ruprecht, Dana Farber Cancer Institute and NIAID, DAIDS

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.

References:

Lakhashe, S. K., Velu, V., Sciaranghella, G., Siddappa, N. B., Dipasquale, J. M., Hemashettar, G., . . . Ruprecht, R. M. (2011). Prime-boost vaccination with heterologous live vectors encoding SIV gag and multimeric HIV-1 gp160 protein: efficacy against repeated mucosal R5 clade C SHIV challenges. *Vaccine*, 29(34), 5611-5622. doi:10.1016/j.vaccine.2011.06.017 [PUBMED](#)

Lakhashe, S. K., Wang, W., Siddappa, N. B., Hemashettar, G., Polacino, P., Hu, S. L., . . . Rasmussen, R. A. (2011). Vaccination against heterologous R5 clade C SHIV: prevention of infection and correlates of protection. *PLoS One*, 6(7), e22010. doi:10.1371/journal.pone.0022010 [PUBMED](#)

Siddappa, N. B., Watkins, J. D., Wassermann, K. J., Song, R., Wang, W., Kramer, V. G., . . . Ruprecht, R. M. (2010). R5 clade C SHIV strains with tier 1 or 2 neutralization sensitivity: tools to dissect env evolution and to develop AIDS vaccines in primate models. *PLoS One*, 5(7), e11689. doi:10.1371/journal.pone.0011689 [PUBMED](#)

Song, R. J., Chenine, A. L., Rasmussen, R. A., Ruprecht, C. R., Mirshahidi, S., Grisson, R. D., . . . Ruprecht, R. M. (2006). Molecularly cloned SHIV-1157ipd3N4: a highly replication-competent, mucosally transmissible R5 simian-human immunodeficiency virus encoding HIV clade C Env. *J Virol*, 80(17), 8729-8738. doi:10.1128/JVI.00558-06 [PUBMED](#)

Watkins, J. D., Siddappa, N. B., Lakhashe, S. K., Humbert, M., Sholukh, A., Hemashettar, G., . . . Ruprecht, R. M. (2011). An anti-HIV-1 V3 loop antibody fully protects cross-clade and elicits T-cell immunity in macaques mucosally challenged with an R5 clade C SHIV. *PLoS One*, 6(3), e18207. doi:10.1371/journal.pone.0018207 [PUBMED](#)

NOTE:

Acknowledgment for publications should read "The following reagent was obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: SHIV-1157ipEL-p from Dr. Ruth Ruprecht and DAIDS, NIAID." Also include the appropriate references cited above in any publications.

Last Updated:

August 16, 2017

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.